Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis
Open Access
- 24 February 2014
- Vol. 4 (2), e004145
- https://doi.org/10.1136/bmjopen-2013-004145
Abstract
Objective Although the values of soluble mesothelin-related peptides (SMRPs), including mesothelin and megakaryocyte potentiating factor, in serum and/or pleural fluid for diagnosing malignant pleural mesothelioma (MPM) have been extensively studied, the exact diagnostic accuracy of these SMRPs remains controversial. The purpose of the present meta-analysis is to update the overall diagnostic accuracy of SMRPs in serum and, furthermore, to establish diagnostic accuracy of SMRPs in pleural fluid for MPM. Design Systematic review and meta-analysis. Methods A total of 30 articles of diagnostic studies were included in the current meta-analysis. Sensitivity, specificity and other measures of accuracy of SMRPs in serum and pleural fluid for the diagnosis of MPM were pooled using random effects models. Summary receiver operating characteristic curves were used to summarise overall test performance. Results The summary estimates of sensitivity, specificity, positive likelihood ratio, negative likelihood ratio and diagnostic OR were 0.61, 0.87, 5.71, 0.43 and 14.43, respectively, for serum and 0.79, 0.85, 4.78, 0.30 and 19.50, respectively, for pleural fluid. It was also found that megakaryocyte potentiating factor in serum had a superior diagnostic accuracy compared with mesothelin for MPM. Conclusions SMRPs in both serum and pleural fluid are helpful markers for diagnosing MPM with similar diagnostic accuracy. The negative results of SMRP determinations are not sufficient to exclude non-MPM, and the positive test results indicate that further invasive diagnostic steps might be necessary for the diagnosis of MPM.Keywords
This publication has 56 references indexed in Scilit:
- Serum Biomarkers in Patients with Mesothelioma and Pleural Plaques and Healthy Subjects Exposed to Naturally Occurring AsbestosLung, 2013
- A prospective trial evaluating the role of mesothelin in undiagnosed pleural effusionsEuropean Respiratory Journal, 2012
- Diagnostic and Prognostic Value of Soluble Mesothelin-Related Proteins in Patients with Malignant Pleural Mesothelioma in Comparison with Benign Asbestosis and Lung CancerJournal of Thoracic Oncology, 2008
- Comparison of Osteopontin, Megakaryocyte Potentiating Factor, and Mesothelin Proteins as Markers in the Serum of Patients with Malignant MesotheliomaJournal of Thoracic Oncology, 2008
- Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: Evaluation in comparison with mesothelinLung Cancer, 2008
- Soluble Mesothelin-Related Peptide Level Elevation in Mesothelioma Serum and Pleural EffusionsThe Annals of Thoracic Surgery, 2008
- Diagnostic accuracy of tumour markers for malignant pleural effusion: a meta-analysisThorax, 2008
- MESOMARK™: A Potential Test for Malignant Pleural MesotheliomaClinical Chemistry, 2007
- Molecular tumor markers for asbestos‐related mesothelioma: Serum diagnostic markersPathology International, 2006
- Combining independent studies of a diagnostic test into a summary roc curve: Data‐analytic approaches and some additional considerationsStatistics in Medicine, 1993